Grifols, S.a. Class A · BME:GRF
Grifols, S.a. Class A — Investor Day (June 2022)
172 slides from Grifols, S.a. Class A's investor day presentation, Jun 30, 2022
Slide 1: June 30, 2022
Sika © June 30, 2022
Slide 2: Disclaimer
Disclaimer This document has been prepared by GRIFOLS, S.A.(GRIFOLS or the “Company”) exclusively for use during the 2022 Investor and Analyst Day on June 30, 2022. Therefore, it cannot be disclosed or made public by any person or entity with an aim other than the one expressed above, without the pr
Slide 3: Agenda
Agenda Time (all in CET) Topic 10:30-11:00 am Breakfast 11:00-11:05 am Welcome Nuria Pascual 11:05-11:15 am Introductory Remarks Raimon Grifols 11:15-11:50 am Plasma Peter Allen 11:50-12:00 am Egypt and Canada Daniel Fleta 12:00-12:45 am Biopharma William Zabel, Joana Sàbat 12:45 am-1:00 pm Diagnost
Slide 4: Introductory Remarks
GRIFOLS 2022 Investor & Analyst Day INTRODUCTORY REMARKS Strengthening Our Mission to Improve Patients’ Life Sustainably Raimon Grifols, co-CEO
Slide 5: Grifols has supported patients amid unprecedented times
5 Grifols has supported patients amid unprecedented times through the generosity of its donors and commitment of its 25,000 employees Reinforcing our mission through a sustainable approach, strengthening… Plasma Supply Innovation Reorganization Note: Biotest employees included in the 25,000 figure
Slide 6: Broadening our global footprint of 400+ centers
Broadening our global footprint of 400+ centers Expanding and Diversifying Our Plasma Network, Capacities and Capabilities Reinforcement of Plasma Supply in the Past 2 Years… Note: plasma centers as of June 30, 2022; SRAAS not included in the 400+ figure as it is not fully consolidated in Grifols’ f
Slide 7: Strengthening our fractionation capacity
Strengthening our fractionation capacity Broadening our global footprint of 400+ centers Expanding and Diversifying Our Plasma Network, Capacities and Capabilities … Sees the Business Strongly Positioned Today Note: plasma centers as of June 30, 2022; SRAAS not included in the 400+ figure as it is n
Slide 8: Innovation ecosystem bolstered with Biotest acquisition
8 Bolstered With the Biotest Acquisition Innovation Ecosystem to Drive Growth and Profitability Innovation ecosystem Immunology Hepatology & Intensive Care Neurology Hematology Pulmonology Others Infectious diseases 7 therapeutic areas reinforces our pipeline 3 key projects to drive revenue growth a
Slide 9: Streamlining Our Organizational Model
9 Streamlining Our Organizational Model… Plasma Supply Innovation Reorganization Previous structure Commercial Division Industrial Division Corporate Services Co-CEOs Bioscience Diagnostic Hospital Bioscience Industrial Group Diagnostic Industrial Group Quality Bio Supplies Division
Slide 10: The New Grifols
10 The “New Grifols” … To Strengthen the Core Plasma Supply Innovation Reorganization Biopharma Plasma Procurement Diagnostic Bio Supplies Others (Healthcare Solutions) Operations (Key support functions to drive Business Units’ performance) Services (Corporate services extended to all Grifols areas)
Slide 11: First in the industry to have a set of policies
11 The First in the Industry to Have a Set of 3 Policies Reflecting Our Commitments Operating With a Sustainable Approach Pioneers in developing a Plasma Donors Policy Underscoring our respect for Human Rights Reconfirming our pledge to Patients and Patient Organizations 30 Goals for 2030 across the
Slide 12: Commitment to Donors and Patients
Commitment to Donors and Patients Donors and Patients: At the Heart of Our Operations €1,800M+ €28,600M+ positive impact of 4 main plasma proteins (IG, Albumin, Alpha-1, pd Factor VIII) Social Value For PATIENTS For DONORS €700M+ For LOCAL COMMUNITIES dedicated to patient advocacy groups and organiz
Slide 13: Impact on Society
Impact on Society Enhancing Our Operations’ Multiplier Effect Combined impacts in Spain, U.S., Germany and Ireland (vs. 140,000 in 2020) 141,500 jobs created 60% stemming from plasma centers €7,700M economic impact (vs. €7,500M in 2020) 40% stemming from plasma centers Socio-economic Impact Our Foun
Slide 14: Grifols Talent
25,000 employees 98 nationalities Grifols Talent Our Team Is in Our Top Priorities 60% women 65% promotions are women 41% senior managers are women +2.8 million total training hours 93% online training hours Spain 3.2%1 U.S. 2.1%2 Germany 0.5% Adjusted Pay Gap Ireland 0.1% Diversity and inclusion Ta
Slide 15: Environmental Responsibility
Environmental Responsibility Building On Our Ambitious 2030 Environmental Goals -55% (from -40%) GHG emissions per unit of production +15% energy efficiency per unit of production 100% (from 70%) electricity consumption from renewable energies Mobility decarbonization in business travel and commutes
Slide 16: Recognized Among the World's Most Sustainable Companies
Recognized Among the World’s Most Sustainable Companies The new Sant Cugat (Barcelona) office building and auditorium awarded LEED Gold certification (Leadership in Energy & Environmental Design) 16
Slide 17: Plasma
GRIFOLS 2022 Investor & Analyst Day PLASMA Leveraging a Unique Combination of Plasma Capacity & Capabilities to Accelerate Performance Peter Allen, EVP Plasma U.S.
Slide 18: Three Pillars for Sustained Growth and Profitability
Expanding global plasma collections with the highest standards of quality and safety 1 Leveraging integrations through technology, standardization and efficiencies 2 Donor & Employee experience excellence 3 Ensuring Sustained Growth and Profitability Through Three Pillars A Unique Combination of Pla
Slide 19: Successfully Executing Our Strategic Plan
19 Successfully Executing Our Strategic Plan… Through SRAAS 41 47 Germany 1 Austria 48 Europe Contract Manufacturing Agreement: Canada Contract Manufacturing Agreements: Spain, Italy and Slovak Republic Note: Number of plasma centers as of December 31, 2020; SRAAS not included as it is not fully con
Slide 20: Broad Global Footprint of 400+ Centers
20 … to Consolidate a Broad Global Footprint of 400+ Centers Through SRAAS 342 41 57 Germany 3 Austria Czech Republic 11 Hungary 18 89 Europe 10 1 343 North America Middle East and Africa 150 159 171 190 257 295 312 366 2014 2015 2016 2017 2018 2019 2020 2021 2022 442 x2.9 Expansion of our plasma-ce
Slide 21: Accelerating Plasma Collection Throughout 2022
21 On Track to Satisfying Growing Plasma Demand Accelerating Plasma Collection Throughout 2022 1 Comparing first 4 weeks of 2022 with last 4 weeks of 2022 (as of week 25) 2 Comparing first 25 weeks of 2022 with first 25 weeks of 2021 60 70 80 90 100 110 120 130 140 Q1 Q3 Q4 2020 Q2 Q1 Q3 Q4 2021 Q2
Slide 22: Tailwinds and Headwinds for Plasma Collection
22 On Track to Satisfying Growing Plasma Demand Accelerating Plasma Collection Throughout 2022 + Tailwinds - Headwinds • Current macro-economic context drives momentum • Contribution from new and recently acquired centers • Regular centers return to pre-pandemic weekly levels • New donor compensatio
Slide 23: Global Plasma Market Position
23 Global Plasma Market Position Supports Leadership in Plasma-Proteins Market Share 22% 26% 26% 25% 10% 15% 20% 25% - 10.000.000 20.000.000 30.000.000 40.000.000 50.000.000 60.000.000 2018 2019 2020 2021 Industry (PPTA & EPA) Donations Grifols Contribution 29% 30% 28% 29% 29% 71% 70% 72% 71% 71% Gr
Slide 24: Strong Integration Response Led to Efficiency Gains
24 A Strong Integration Response Led to Greater Efficiency Gains Rapid Inorganic Expansion Over the Past 4 Years Acquisitions Integrations • Operations • Quality and safety • Shared services systems • Donor management applications and communications • Technologies • Human resources • Culture Consist
Slide 25: Increasing Business Process Optimization
25 • Improved documentation and workflow • Automated paperless manufacturing records using handheld computing devices • Streamlined process flows and reduction of manual verification steps thanks to software automation • Labor optimization via paperless and process automation • Donor screening devic
Slide 26: New Devices Enhance Donor and Employee Experience
26 New Devices Enhance Donor and Employee Experience Leveraging Technology to Optimize Ongoing Efficiencies 0 50 100 150 200 250 2021 2022 2023 NexSys/Aurora Xi Legacy PCS Digital Transformation Device migration Benefits • NexSys designed with data management, safety features and usability enhanceme
Slide 27: Process Enhancement From Different Approaches
27 Process Enhancement From Different Approaches Leveraging Our Capabilities • Diversify the donor demographics to expand the unique donor count • Focus on donor retention and donation frequency by high service delivery • Reduce complexities in the donor center towards standardization of our systems
Slide 28: Delivering on Improvements
28 Delivering on Improvements Derived From Optimizing Diversification Leveraging Technology to Optimize Efficiencies 2021 2022 Technology delivering better targeting for donor recruitment, while enhancing donor experience and loyalty: • Legacy BECS transitioned out • Electronic System Appointment •
Slide 29: Average Liters per Center Demonstrate Positive Momentum
29 Communication Programs Delivering the Potential Average Liters per Center Demonstrate Positive Momentum Average Liters per Center* Donor experience focus & marketing campaigns partially offset by U.S. incentive plans and Delta variant. Gradually improving over the quarters Recovery delayed due to
Slide 30: Higher Donor and Employee Engagement and Retention
30 Higher Donor and Employee Engagement and Retention Delivering on the employee and donor experience makes the difference, what ensures Grifols can withstand competition and market fluctuations Mastering Both Experiences Enables Achieving the Average Liters per Center Target Employee and Donor Expe
Slide 31: Employee Experience Directly Impacts Donor Experience
EMPLOYMENT TENURE PRE-EMPLOYMENT and ONBOARDING Grifols’ Employees Proudly Help Patients Around the World Employee Experience Directly Impacts the Donor Experience Opportunities for advancement, engagement, progressive training and skill enhancement IN-CENTER EXPERIENCE Reputation for industry recru
Slide 32: Success Depends Upon the Donor Experience
Donors Feel Good Knowing Their Plasma Helps Patients Around the World Success Depends Upon the Donor Experience POST DONATION PRE-DONATION Ongoing dialogue and predictive digital communications inspire donor promotion IN-CENTER EXPERIENCE Multi-channel communications with strong digital presence tar
Slide 33: Technology and Data Infrastructure Support Donor Experience
Technology and Data Infrastructure Support Donor Experience The Development of Donor Experience Data tools and CRM Trigger rules, automation Revenue management Predictive AI Analyze data and tools ORCHESTRATION INTEGRATION Donor direct content (email, SMS, apps, servicing tools, chatbots) Future don
Slide 34: Donor recruitment campaign: U.S.
34 Moving forward… • Continue to build awareness and engagement with future donors, using uninterrupted recruitment campaigns • Gained momentum, building on continued learnings to expand and refine recruitment messaging and tactics • Expand digital presence across channels to secure market leadershi
Slide 35: Building Momentum Through U.S. Recruitment Campaigns
35 Successfully Encouraging People to Donate Plasma Building Momentum Through Our U.S. Recruitment Campaigns • Raised broad awareness on the benefits and need of plasma donations • Recruited new donors and recapture donors who lapsed in plasma donations • Reinforced messaging of life saving medicine
Slide 36: Donor recruitment campaign: Germany
36 Moving forward… • Expand digital tools and insights of donors needs and motivation for data-driven marketing campaigns • Delimitation from competitors and leadership by using donor-experience technologies and services • Greater awareness of plasma donation is indispensable to produce life-saving
Slide 37: German campaign performance
37 1.806 2.308 2.672 2.509 2.360 2.444 32.304 35.852 41.739 38.989 37.257 40.074 610 1.500 2.440 3.050 4.270 3.980 ✓ Extension of the targeted demographics from young to older ✓ Expansion of leadership position in social media & online among competitors ✓ Development of data-driven marketing along t
Slide 38: Leveraging a Unique Combination of Plasma Capacity & Capabilities
38 Leveraging a Unique Combination of Plasma Capacity & Capabilities to Accelerate Performance Double-digit plasma growth addresses expected plasma needs for 2022 to meet strong underlying demand Current macro-economic context drives momentum on plasma collections Successful execution of expansion p
Slide 39: Canada and Egypt
GRIFOLS 2022 Investor & Analyst Day CANADA AND EGYPT Responding to the Global Need for a Sustainable Plasma Model Daniel Fleta, Chief Industrial Officer
Slide 40: Game-Changing Initiatives to Become a Blueprint
40 Game-Changing Initiatives to Become a Blueprint for Other Countries Responding to the Global Need for a Sustainable Plasma Model New indications and higher- prevalence diseases Diagnosis and prescriptions are increasing COVID-19 pandemic Increased emphasis on the importance of plasma supply and i
Slide 41: Self-Sufficiency Management Models
41 Self-Sufficiency Management Models Responding to the Global Need for a Sustainable Plasma Model • 1,000+ private plasma donation centers • 80+ private plasma and blood donation centers • Compensation (legal limitations) • Public Infrastructure • Grifols provides know-how • Construction of plasma
Slide 42: Fractionation Capacity Global Footprint
42 Fractionation Capacity Global Footprint Ensuring Sufficient Capacity 22mL as of today (June 2022) 26mL in 2026 U.S. Spain Ireland Germany Canada Egypt 42 U.S. Spain Ireland Germany
Slide 43: Canada: Leveraging Our Experience and Capabilities
43 Well-Positioned to Satisfy the Country’s Needs Canada: Leveraging Our Experience and Capabilities… Grifols has a local fractionation, purification and fill & finish plant Canadian plasma-derived therapies market Mature and stable market with high consumption of IgG levels … but Canadian governmen
Slide 44: Grifols Canada Therapeutics Location
44 GCT Downtown Airport Grifols Canada Therapeutics (GCT) Canada Egypt Strategic Location Montreal
Slide 45: Canada Site Facts
45 Canada Site Facts Construction of a New State-Of-The-Art Plant Acquired by Grifols October 1, 2020 Located in Technoparc Montreal, Quebec Plot: 63,134 m2 Built: 19,865 m2 3-story building Manufacturing, warehouse & QC lab and admin building Canada Egypt
Slide 46: Canada Current Facility
46 Canada Current Facility Canada Egypt
Slide 47: Canada Expansion Project Construction
47 Phase I August 22 +6,600 m2 Canada Expansion Project Construction Gamunex Expansion Fractionation Expansion Warehouse Expansion Albumin Purification Canada Egypt Phase II Sept ’23 Phase III Nov ’24
Slide 48: Albumin Conversion – Phase I
48 Albumin Conversion – Phase I, August 2022 Canada Egypt Albumin Purification
Slide 49: Egypt: Delivering On Our Promises
49 National mandate to develop the healthcare system Plasma-derived medicines needed for its growing population Government committed to the country’s self-sufficiency Overcoming Challenges to Strengthen Egypt’s Healthcare System Egypt: Delivering On Our Promises Through a Pioneering Model Establish
Slide 50: Year 1: Grifols Laid the Foundations of the Egypt Project
50 Apr 15 20 donor- center network Fractionation plant Purification plant 1st plasma shipment to Spain Achievements Clear the Path for Future Milestones Master Joint Venture Agreement Signature 2020 Grifols Egypt first employee Testing laboratory operational Egypt executive regulation for plasma rel
Slide 51: First Integrated Plasma-Supply Platform in Africa
51 Paving the Way for the First Integrated Plasma-Supply Platform in Africa First EDA1 Licensed Donor Center in Egypt Donor center, plasma testing labs, plasma freezers warehouse, Grifols Academy for Plasmapheresis and plasma operations offices 1 Egyptian Drug Authority (EDA) Canada Egypt
Slide 52: Plasma Collection Centers Projected
52 10 Plasma Collection Centers Projected in Wave 1 (10+ in Wave 2) Plans on Track for the Construction of 20 Donor Centers 1st Zone SOUTH CAIRO 2nd Zone EAST CAIRO 3rd Zone CANAL ZONE Maadi Helwan Misr Al Gadida Military Institute Nasr City Port Said Suez Tal Kabeer Ismailia Canada Egypt DC Wave 1
Slide 53: Manufacturing Site Construction
53 Canada Egypt Plans on Track for the Manufacturing Site Construction New Administrative Capital
Slide 54: Key Takeaways
54 Key Takeaways Responding to the Global Need for a Sustainable Plasma Model Self-sufficiency is crucial to guarantee the sustainability of plasma-derived medicines supply Grifols positions to serve as a best-in-class partner through private or public/private initiatives to support a sustainable pl
Slide 55: Biopharma
GRIFOLS 2022 Investor & Analyst Day BIOPHARMA Poised for Performance in an Essential and Growing Market Bill Zabel, EVP Commercial Operations Joana Sabat, SVP Global Marketing & Market Access
Slide 56: Poised for performance
Poised for performance… … in an essential and growing market 56
Slide 57: Grifols Is Well Positioned to Get Back to Growth
57 Driven by Biopharma Strengths Grifols Is Well Positioned to Get Back to Growth 1 The Worldwide Plasma Proteins Market, MRB, February 2022 Global plasma-derived proteins market is an attractive market that continues to grow FY20 sales EUR 25Bn€ (7.2%1 CAGR 2017-2020) Uniquely positioned with a spe
Slide 58: Bioscience Revenues and Core Growth Products
58 7.9% 8.0% 8.9% 7.6% -5.9% 2017 2018 2019 2020 2021 2022 Bioscience Revenues (EUR in millions, growths at cc) Pandemic impact CAGR: +8.1% 2022 Core growth products show positive trend in Q1’22 vs. Q1’21 Strong start of the year, driven by sales in China and U.S. Albumin Back to growth, driving Bio
Slide 59: Main Geographies Show Recovery
59 Main geographies show significant recovery in Q1’22 vs. Q1’21 Underlying Demand Supports Further Growth 7.9% 8.0% 8.9% 7.6% -5.9% 2017 2018 2019 2020 2021 2022 Bioscience Revenues (EUR in millions, growths at cc) Pandemic impact 2022 Strong albumin growth driving double-digit-growth China Recover
Slide 60: Focus on Therapeutic Areas
60 Deep Knowledge and Capabilities Coupled With a Focus on Therapeutic Areas Building on Biopharma Portfolio With Recent Product Launches Immunology and Neurology Treating immune deficiencies and autoimmune disorders Pulmonology Treating AATD1, a genetic condition that can lead to serious lung disea
Slide 61: Gamunex-C #1 Prescribed IG for CIDP
61 Gamunex®-C Recognized as the #1 Prescribed IG for CIDP Immunology and Neurology Leading an Increasingly Competitive U.S. CIDP1 Market CIDP Market Source: LexisNexis Trending Data, Medical Claims only; and Gamunex®-C and GammaKed share a J-code 1 Chronic Inflammatory Demyelinating Polyneuropathy (
Slide 62: Xembify Continues to Gain U.S. Market Share
62 Over 1,000 U.S. HCPs have prescribed Xembify® since its launch and 87% continue to prescribe it +141% YoY LTM2 March’22 +3% -5% -1% +3% +1% Competitor C Competitor A Competitor B Competitor D volume growth since launch… doubled market share in a year Immunology Supporting Patients by Providing a
Slide 63: SCIG Expansion to New Geographies
63 Immunology SCIG Represents 23% of Volume in EU/Australia … While Expanding to New Geographies Outside the U.S. Sources: (i) Grifols Database provisional data 2021 (accessed May’22); (ii) Grifols ATU Study 2022. Base: All HCPs. Germany (n=40), France (n=40), Italy (n=40), Spain (n=40) UK (n=40) No
Slide 64: Prolastin Shows Steady Growth
64 Pulmonology Prolastin®1 Shows Steady Growth in 2021 and Q1’22 Leading the Alpha-1 Market for 35 Years Source: Grifols Internal data 1 Prolastin® includes all Grifols Alpha-1 brands Steady growth… Jan 2021 Dec 2021 March 2022 FY21 Q1’22 … in the Alpha-1 antitrypsin market (worldwide market in 2021
Slide 65: Prolastin Access and Patient Support Programs
65 Helping ensure HCPs and patients have access to Prolastin® when and where it is needed Patient health management programs provide personalized care and home infusion Pulmonology Leading the Alpha-1 Market for 35 Years Prolastin®1 Shows Steady Growth in 2021 and Q1’22 Sustained and reliable produc
Slide 66: HyperRAB Driving Hyperimmunes Portfolio
66 Record Sales in 2021 HyperRAB® Driving Hyperimmunes Portfolio Infectious diseases Rabies IG Market (2021) HyperRAB® >80% Graph source: Grifols Database provisional data 2021 (accessed May’22) 1 Human rabies immune globulin (HRIG) 2 HyperRAB (rabies immune globulin [human]) Prescribing Information
Slide 67: Albutein FlexBag Successful Launch
67 Intensive care & Hepatology Designed, Engineered and Manufactured by Grifols Albutein FlexBag™ Successful Launch Albutein FlexBag™ 18% of U.S. Albutein® sales in 2022 Q2 21 Q3 21 Q4 21 Q1 22 launch … reflected in revenues backed by fast adoption in the U.S. 5% launch First and only 5% 500mL offer
Slide 68: Tavlesse Continues to Gain Traction
68 Sales volume (last 12 months) On track throughout 2021 First launching country Germany Successfully Launched in Multiple European Countries, Including EU41 Tavlesse® Continues to Gain Traction Sources: Internal data; (i) Price and Reimbursement ; (ii) Health Technology Assessment 1 Includes Franc
Slide 69: Vistaseal Market-Leading Fibrin Sealant
69 Nordics, Puerto Rico, France, Singapore, Netherlands 2021 Ongoing joint development of innovative solutions 2nd plasma protein sourced from Grifols approved in the U.S. Recovery of Elective Surgical Procedures Following Pandemic-Related Interruptions Vistaseal® Market-Leading Fibrin Sealant in th
Slide 70: Operating in an essential and growing market
Poised for performance… … in an essential and growing market 70
Slide 71: Growth in IG Market Driven by PI Diagnosis
71 Operating in an Essential and Growing Market Further Growth in IG Market Driven by Progress in PI1 Diagnosis Average diagnosis 12.4 years2 Undiagnosed 70-90%3 >400 related-genetic defects5 500,000 undiagnosed 4 PI underdiagnosis facts Immunology 1 Primary Immunodeficiency (PI) 2 Routes J, et al.
Slide 72: PI underdiagnosis and partnering
72 Immunology Operating in an Essential and Growing Market Further Growth in IG Market Driven by Progress in PI1 Diagnosis PI underdiagnosis facts 1 Primary Immunodeficiency (PI) 2 Routes J, et al. J Clin Immunol. 2016;36:450-461 3 Primary Immunodeficiencies (PID) – Driving Diagnosis for Optimal Car
Slide 73: SID Market Expands in Hematological Malignancies
73 2020 2027 Immunology and Neurology Plans on Track for Xembify® to Treat New Key Indications e.g., CLL1 and HGG2 SID Market Continues to Expand in Hematological Malignancies 1 Chronic Lymphocytic Leukemia (CLL) 2 Hypogammaglobulinemia (HGG) 3 US PPTA Distribution Data 4 Friman V et al. Hematol Onc
Slide 74: Accelerating AATD Diagnosis as Our Primary Goal
74 >950,000 tests performed Grifols’ worldwide testing program (since 2006) >205,000 deficient patients found >16,000 severe patients diagnosed (vs. >850,000)(vs. >190,000)(vs. >15,000) in Jun’2021 in Jun’2021 in Jun’2021 Further Expanding Our Testing Program Worldwide Pulmonology Accelerating AATD1
Slide 75: Dedicated Efforts to Increase the Diagnosis Ratio
75 Dedicated Efforts to Increase the Diagnosis Ratio Pulmonology Undiagnosed Alpha-1 patients >90% Accelerating AATD1 Diagnosis as Our Primary Goal 1 Alpha-1 Antitrypsin Deficiency (AATD) 2 Campos MA, Wanner A, Zhang G, et al. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin d
Slide 76: Increasing Albumin Opportunity in Critical Care
76 Grifols Hepatology Program Intensive care & Hepatology Potentially Increasing Albumin Opportunity in Critical Care Supporting Regular Albutein®1 Use as a Disease Modifying Treatment 1 Albutein® includes all Grifols albumin brands 2 Non-alcoholic fatty liver disease 3 2022 NAFLD Endocrinology-AASL
Slide 77: Key Takeaways
77 Key Takeaways Poised for Performance in an Essential and Growing Market Global plasma-derived proteins market is an attractive market that continues to grow IG, Alpha-1 and albumin defy the normal life-cycle of a pharmaceutical product and keep growing Strong key brands: Gamunex®, Xembify®, Prola
Slide 78: Diagnostic
GRIFOLS 2022 Investor & Analyst Day DIAGNOSTIC Evolving Business Model to Strengthen Competitiveness Antonio Martinez, President Diagnostic
Slide 79: A New Leadership to Accelerate Diagnostic
79 A New Leadership to Accelerate Diagnostic Antonio Martínez President Operations R&D Industrial, Quality & Regulatory Sales & Marketing Customer Technical Service Supply & Demand Planning Controlling Focus and deep knowledge within the Diagnostic Business Unit Project Management Office (PMO) Allia
Slide 80: Diagnostic Mission
80 Diagnostic Mission Improving care for donors and patients by providing laboratorians with innovative diagnostics tools 80
Slide 81: Three Strategic Pillars
81 Growing the Business Based On Three Strategic Pillars Consolidate and strengthen current business 1 Support Biopharma 2 Regulatory innovation & digital transformation 3 81
Slide 82: Combining Capabilities to Accelerate Growth
82 TMA3 PoC4 NGS5 PCR6 Combining Capabilities to Accelerate Growth Platforms Regulatory Knowledge Global Sales & Customer Technical Support Proprietary/Partnership Technology CLIA1 Labs in U.S. & Europe R&D capabilities & manufacturing facilities of In Vitro Diagnostic (IVD) devices Extensive regula
Slide 83: Diagnostic Division Reported Solid Growth in 2021
83 Driven by COVID-19 Innovation and Strong Underlying Business Diagnostic Division Reported Solid Growth in 2021 Core business of NAT achieved sustained growth and continued to consolidate in the main markets (U.S. and China) 732 702 734 776 779 2017 2018 2019 2020 2021 Clinical Diagnostic & Others
Slide 84: Strategic Partnerships and Alliances
84 Strategic Partnerships and Alliances to Drive Further Growth Increasing Presence in Key Markets Key collaboration agreements Strategic long-term partner for Diagnostic: • Consolidation of current business • Innovation in partnership with a leading testing player • Growth: developing new assays fo
Slide 85: Immunohematology Market Delivering Strong Growth
85 Expanding Grifols’ Blood Collection Capabilities Immunohematology Market Delivering Strong Growth New red blood cells manufacturing facility in San Diego BTS constant growth led by DG Gel® System sales and fueled by Erytra Eflexis® Worldwide market penetration >7,000 instruments 50M gel cards ach
Slide 86: Successful Alpha-1 Testing Strategy
86 Successful Alpha-1 Testing Strategy Supporting Biopharma Through High-ROI1 Programs Grifols’ testing program continues to accelerate diagnostic globally - Cost-effective - FDA approved - Scientific Societies Support Life-saving therapy for those patients who need it >950,000 tests performed >205,
Slide 87: Our Journey to an Innovative Program
87 Our Journey to an Innovative Program… 2017 2021 2018 2019 2020 2022 Spanish launch Successful with extremely positive feedback LATAM launch Main countries (Argentina, Brazil, Chile and Colombia) U.S. Launch AlphaID™ buccal swab German launch Alphakit Dry Blood Spot (DBS) Clinical trial U.S. popul
Slide 88: Over The Counter 510(k) Filing to FDA
88 Over The Counter innovative solution to expand the U.S. screening program Over The Counter 510(k) Filing Submitted to FDA: AlphaID™ at Home … To Achieve a New Milestone May 2022 FDA SUBMISSION The program is ready to launch once cleared
Slide 89: Expanding the Model to Support Biopharma Growth
89 Beyond hATd3/ATIII4 patients While Embracing Future Initiatives Including Biotest Projects Expanding the Model to Support Biopharma Growth Pharma programs Alpha-1 patients Basis for innovative testing strategies PI1/SID2 patients 1 Primary Immunodeficiency (PI) 2 Secondary Immunodeficiency (SID)
Slide 90: Compliance With IVDR
90 Promonitor Quick IFX one of the first near-patient testing devices approved under the IVDR Grifols, Already Compliance With New In Vitro Diagnostics Medical Devices European Regulation (IVDR) Grifols will ensure on-time delivery of IVDR certification for all relevant products First Certifications
Slide 91: Advanced Software Solutions and New Customer Portal
91 Advanced Software Solutions and a New Customer Portal Digital Transformation Promotes Higher Performance Key strategic solutions to streamline customer operations 1 2 New middleware solution connecting blood typing data across laboratory network system to improve patient care, enhance operational
Slide 92: Key Takeaways
92 Key Takeaways Evolving Business Model to Strengthen Competitiveness Strengthened leadership to increase effectiveness and drive efficiencies Broad portfolio of platforms, assets and global presence to outperform competition and grow value Secured U.S. key large customer while poised to increase p
Slide 93: Sika ©
Sika © June 30, 2022
Slide 94: Innovation
GRIFOLS 2022 Investor & Analyst Day INNOVATION Accelerating Innovation: Gaining.Focus and Speed in Our Pipeline Albert Grifols Coma;-Cros, Chief limnovation-Officer César Cerezo, SVP Drug Development Carter Keller, SVP GigaGen
Slide 95: Accelerating Innovation Through Key Objectives
95 Accelerating Innovation Through 3 Key Objectives Gaining focus and speed in our pipeline (from past to present) 2 Building new innovation models (paving the future) 3 Further evolving our innovation organization 1
Slide 96: Focus on Scientific Areas While Elevating Controlling and PMO
96 Focus on Scientific Areas While Elevating Controlling and PMO1 Gaining focus and speed in our pipeline (from past to present) 2 Building new innovation models (paving the future) 3 Further evolving our innovation organization 1 1 Project Management Office Greater discipline in accountability & ex
Slide 97: Rationalizing Portfolio & Establishing Result-Oriented Processes
97 Rationalizing Portfolio & Establishing Result-Oriented Processes Building new innovation models (paving the future) 3 Further evolving our innovation organization 1 Gaining focus and speed in our pipeline (from past to present) 2 + Clear direction with a 2030 Ambition target Stronger business-wei
Slide 98: Developing a 360-Degree Innovation Ecosystem
98 New Approaches: Developing a 360-Degree Innovation Ecosystem Gaining focus and speed in our pipeline (from past to present) 2 Further evolving our innovation organization 1 Building new innovation models (paving the future) 3 Driving growth… Digital & Data China Strategic Alliances & Initiatives
Slide 99: Balanced Risk-Value Pipeline
99 Balanced Risk-Value Pipeline Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Phase 4 / Regulatory LCM Immunology ++ recIG Spike in PdIG with enriched recombinant libraries (PI) IVIG-PEG Xembify® Europe Xembify® Prefilled syringes IVIgG Next Gen PI Xembify® Bi-weekly dose Xembify® in CLL Hepatology
Slide 100: Notable Progresses in Core Projects
100 Notable Progresses in 4 Core Projects AMBAR-Next in Alzheimer's 1 Xembify® in CLL 2 ATIII in sepsis 3 GigaGen & HBV1 4 1 Hepatitis B Virus (HBV) Disease background R&D
Slide 101: Alzheimer's Disease Therapy: An Urgent Unmet Need
101 5th Leading Cause of Death Worldwide Alzheimer’s Disease Therapy: An Urgent Unmet Need Worldwide Prevalence % of Dementia Cases By Age Mortality >65y/o Majority are leading cause of mortality 5th dementia cases 60-70% accounts for 200,000 <65 y/o have younger-onset Alzheimer's disease but… Progr
Slide 102: Innovation Strategy in Neurodegenerative Diseases
102 Innovation Strategy in Neurogenerative Diseases (ND) R&D Efforts Encompass the Entire Development Path Understanding of plasma at the molecular level in healthy and disease states Pipeline expansion of therapeutic plasma fractions, small molecules, antibodies Explore therapeutic benefit of plasm
Slide 103: AMBAR-Next Phase 3 Trial
103 Confirmatory Albumin and Plasma Exchange to Treat Alzheimer’s AMBAR-Next: Slowing Clinical Decline of Mild-to-Moderate AD Phase 3 1:1 randomized Double-blinded U.S., Canada, Spain and other EU countries AMBAR- Next ~600 subjects with mild-to-moderate AD 18-month follow-up Plasma exchange treatme
Slide 104: Chronic Lymphocytic Leukemia: Fastest-Growing IG Patient Segment
104 Chronic Lymphocytic Leukemia (CLL) Targeting the Fastest-Growing Patient Segment for IG Therapy Leukemia Prevalence By Age Morbidity and Mortality CLL IG Market Potential 30-50% between avg. at time of diagnosis 72 years Accumulation of monoclonal, mature CD5+B cells in the peripheral blood, bon
Slide 105: Xembify to Prevent Infections in CLL Patients
105 Treating Patients with Concomitant HGG and Recurrent or Severe Infections Xembify® to Prevent Infections in CLL Patients Phase 3 1:1 randomized Double-blinded U.S. only, multi-center ~375 subjects Xembify® + standard medical treatment Placebo + standard medical treatment FDA provided approval to
Slide 106: ATIII in Sepsis: Very High Burden of Healthcare Costs
106 Outlook for U.S. Potential if Treatment Proven ATIII in Sepsis: Very High Burden of Healthcare Costs Xembify® in CLL ATIII in sepsis GigaGen & HBV Patient population: septic shock with disseminated intravascular coagulopathy (DIC) targeted with endpoint versus “C” signature Presumed dose: 30k IU
Slide 107: Collaboration With Endpoint Health
107 Global Collaboration Agreement and Solid Partnership With Endpoint Health Disruptive Diagnostic to Identify Thrombate III Responders Gene expression array (Biocartis device) • IVD test using small blood sample • 15 marker array developed and validated in over 900 sepsis patients • Gene expressio
Slide 108: Building the Future to Treat Severe Sepsis
108 Solid partnership with Endpoint Health (EPH) Xembify® in CLL ATIII in sepsis GigaGen & HBV Building the Future to Treat Severe Sepsis Next Steps Evaluate the feasibility of the Phase III study design with regards to endpoints and mortality event rates So far • Supplying ATIII to conduct clinical
Slide 109: GigaGen Immune Genomics Technology
109 Recombinant polyclonal antibodies World-Leading Immune Genomics Technology for Drug Discovery GigaGen Captures & Recreates Complex Antibody Repertories Xembify® in CLL ATIII in sepsis GigaGen & HBV Capture Re-create Immune repertoire: Human or Humanized Animal Exceptional monoclonal antibodies A
Slide 110: Chronic HBV: Widespread Disease With Significant Morbidity
110 Xembify® in CLL ATIII in sepsis GigaGen & HBV Despite Currently Available Therapies and Vaccines Chronic HBV1: Widespread Disease With Significant Morbidity 1 Hepatitis B Virus (HBV) 2 Global Data report: Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029 3 WHO (https
Slide 111: Anti-HBV Recombinant Polyclonal
111 Anti-HBV Recombinant Polyclonal 0.0001 0.001 0.01 0.1 1 10 100 1000 10000 100000 0 50 100 Concentration [ug/mL] % i n f e c t e d ( n o r m a l i z e d t o n o A b c o n t r o l ) IVIG HBV hyperimmune rHBIG 3rd party mAb in dev Live Virus Neutralization (In Vitro) Humanized Liver HBV Challenge M
Slide 112: rHBIG: the First Chapter
112 rHBIG1: the First Chapter GigaGen’s Antibody Platform Potential • Completely new class of therapeutics uniquely enabled by the GigaGen platform • Capability that Grifols alone possesses • Additional recombinant polyclonal therapeutics for infectious disease, immunology, transplant and other area
Slide 113: Key Takeaways
113 Key Takeaways Accelerating Innovation: Gaining Focus & Speed in Our Pipeline Gaining focus and speed in our pipeline by rationalizing our portfolio and adopting a more result-oriented governance Building new innovation models in digital and data, China and precision medicine Seeking U.S. indicat
Slide 114: Grifols and Biotest
GRIFOLS 2022 Investor & Analyst Day GRIFOLS AND BIOTEST A Transformational Transaction to Maximize Both Opportunities Joana Sabat, SVP Global Marketing & Market Access Jérg Schittrumpf, Biotest Chief Scientific Officer
Slide 115: A Transformational Transaction
115 Grifols and Biotest: A Transformational Transaction Maximizing Opportunities for Both Companies… Geographic fit U.S. 64% Europe 61% Scalability Broader commercial reach U.S. market knowledge and penetration Plasma collection and manufacturing capacity Pipeline acceleration of key novel products
Slide 116: Accelerating Grifols' Innovation Pipeline
116 Bringing in Precision Therapies, Fibrinogen and Trimodulin, and Cytotect® … Accelerating Grifols’ Innovation Pipeline * Project of AlbaJuna (Grifols’ invested company); ** Licensed rights from Rigel Pharmaceuticals in EU and other countries; *** Partnership with Endpoint Health … Biotest project
Slide 117: Fibrinogen: Opportunity to Boost Revenue per Liter
117 Fibrinogen concentrate is a highly pure preparation of human fibrinogen that can be used to safely replace the absence or deficit of fibrinogen safer, much faster and with greater efficiency and precision than the current options of fresh frozen plasma or cryoprecipitates Fibrinogen: An Unparall
Slide 118: Acquired and Congenital Fibrinogen Deficiency
118 • Very rare, inherited bleeding disorder in which the body’s ability to form blood clots is impaired • Fibrinogen is used for treatment and prophylaxis of bleeding episodes in these patients Playing an Essential Role in Blood Clotting and Hemostasis Treating Acquired and Congenital Fibrinogen De
Slide 119: Monitoring Patient Coagulation Status
119 Monitoring Patient Coagulation Status Allows Administering Precise Therapies Most widely-used devices… TEG® ROTEM® Clotting Assessment: Critical to Monitor Deficiency Point-of-Care (PoC) diagnostic…… bringing in positive market implications Source: Benes, Jan et al. “Viscoelastic Methods of Bloo
Slide 120: Promising Results in Both Clinical Trials
120 Promising Results in Both Clinical Trials Congenital FD1 Phase I/III study: Largest clinical trial in congenital fibrinogen deficiency worldwide Treatment of adults and children Results confirm high expectations regarding efficacy and safety… • Expected pharmaco-kinetics and -dynamics (Phase I),
Slide 121: Acquired Fibrinogen Deficiency Indication
121 Acquired Fibrinogen Deficiency Indication: Broader Adoption and Opportunity No indication for Acquired Fibrinogen Deficiency, only congenital use Currently using cryoprecipitate or FFP1 Indication for Acquired Fibrinogen Deficiency Additional evidence would drive broader adoption Fibrinogen cons
Slide 122: Seizing Fibrinogen's Large Market Opportunity
122 +5.9% Improved Point-of-Care diagnostics • Increasing knowledge, availability and reimbursement worldwide Increased awareness • European and Canadian guidelines • Diagnostic companies and plasma- derived medicines companies increasing education on Precision Therapy Change of market dynamics • Sh
Slide 123: Trimodulin: A Potential Blockbuster
123 Unique Polyvalent IG Composition Trimodulin: A Potential Blockbuster • Recognizes pathogens, also part of innate immune system • IgM and IgA can be secreted and are present directly on the pulmonary surface • Strong anti-inflammatory effects by acting through cellular receptors • Scavenge virule
Slide 124: sCAP: A Leading Cause of Illness and Death
124 A High Unmet Medical Need sCAP1: A Leading Cause of Illness and Death Worldwide2 1 Severe community acquired pneumonia: Severe CAP (sCAP) is usually defined as CAP that requires admission to the intensive care unit (ICU) 2 Wunderink 2014, N Engl J Med 370;6. 3 Chest Journal (CHEST) (chestnet.org
Slide 125: Changing the sCAP Treatment Paradigm
125 Trimodulin Improves Patient Response With Further Decrease in Mortality Changing the sCAP1 Treatment Paradigm + Antibiotics/Antivirals Ventilation, hydration, vasopressors… Causal therapy Trimodulin Supportive therapy No comparable adjuvant therapy available Standard Medical Treatment + ✓ oversh
Slide 126: Extensive Development Program in Severe Pneumonia
126 Patient Groups and Disease Stages for Optimal Therapy Identified in Phase II Studies Extensive Development Program in Severe Pneumonia Trimodulin Fibrinogen Cytotect® Pregnancy CIGMA Phase II Completed ESsCOVID Phase II Completed ✓ Very positive feedback from FDA1, EMA2, PEI3 and clinical expert
Slide 127: Phase III Trials Starting 2022
127 COVID-19 patients sCAP patients (Start 2022) (Start 2022) Leveraging on Phase II Results to Start Phase III Trials in 2022 Randomized, placebo-controlled, double-blind, multi-center, phase III trials investigating the efficacy and safety of Trimodulin in adult hospitalized subjects • Subjects on
Slide 128: Potential Addressable Markets
128 Potential Addressable Markets Grifols’ Capacities Help Address the Opportunity sCAP Adjunctive treatment of patients with severe Community Acquired Pneumonia (sCAP) who require invasive mechanical ventilation and have CRP1 >70 mg/L COVID-19 Source: Biotest market research 1 C-reactive protein (C
Slide 129: No Direct Competitors for Trimodulin in sCAP
129 Harnessing the Opportunity to Address a Critical Medical Need No Direct Competitors for Trimodulin in sCAP1 Trimodulin Fibrinogen Cytotect® Pregnancy No direct competitors: no IgM enriched immunoglobulins on the market or in clinical trials High medical need: high mortality rate despite antibiot
Slide 130: CMV Infection: Large Unmet Medical Need
130 No Approved Treatment for This Disease CMV1 Infection: A Disease With Large Unmet Medical Need 81% – 95% >95% 66% – 80% 51% – 65% No data 35% – 50% <35% 1 Cytomegalovirus (CMV) CMV prevalence The most common congenital infection in developed countries 0.3-2.4% prevalence in newborns Infected wom
Slide 131: Very Low Awareness of CMV Infection in Pregnancy
131 Potential Effective Treatment to Increase Awareness and Diagnosis Very Low Awareness of CMV Infection in Pregnancy Disease background Fig: National CMV Foundation; (www.nationalCMV.org) (adapted) CMV disease awareness 100% awareness U.S. children affected per year CMV 30% Trimodulin Fibrinogen C
Slide 132: Cytotect: Tackling CMV
132 First Treatment to Prevent Transmission from the Mother to the Unborn Child Cytotect®: Tackling CMV1 With a High-Potential Specialty Protein It binds to CMV and avoids infections of host cells and presents CMV particles for phagocytosis Modulates and interacts with immune cells (dendritic cells,
Slide 133: Significant Transmission Reduction With CMVIG
133 Significant Transmission Reduction When CMVIG1 Is Administered Clinical Experience Suggests Good Efficacy of Cytotect® Clinical development status Previous prospective, observational study has described success of study protocol 35,2% 6,5% No intervention CMVIG 2 3 1 CMVIG: Cytomegalovirus Immun
Slide 134: PreCyssion Trial
134 Following Primary Maternal Infection With Gestational Age ≤ 14 Weeks PreCyssion Trial: Prevention of Maternal-Fetal CMV Transmission Objective: Demonstrate efficacy and safety of Cytotect® in preventing maternal-fetal transmission of CMV Study Design • Pivotal, clinical Phase III • Open-label •
Slide 135: Success of Cytotect Represents Important Opportunity
135 Success of Cytotect® Represents an Important Opportunity Experts Unveil the Uniqueness of Anti-CMV Number of births per year 3 M 3.6 M EU51 Market opportunity Source: Centers for Disease Control and Prevention (CDC): Congenital CMV Infection | CDC 1 Includes France, Germany, Italy, Spain and Uni
Slide 136: Expected Market Approval
136 Grifols’ Scale and Commercial Strength: Key to Unfold the Full Value of a New Generation of Plasma Medicines Expected market approval Fibrinogen Trimodulin Cytotect® Pregnancy Market opportunity Key considerations • As for now, only European market approval is considered • Intention in the mid-t
Slide 137: Revenue and Margin Potential of New Plasma Medicines
137 Grifols’ Scale and Commercial Strength: Key to Unfold the Full Value of a New Generation of Plasma Medicines Revenues/ Margins Fibrinogen USD 30-50M USD 400-800M • Greater commercial reach • Complementary presence in important markets (US) • Ability to develop new markets Trimodulin Cytotect® Pr
Slide 138: Key Takeaways: Grifols and Biotest
138 Grifols and Biotest: A Transformational Transaction to Maximize Both Opportunities Acquisition enhancing Grifols and Biotest opportunities while accelerating pipeline Expanding and diversifying plasma sourcing by adding 31 European centers and increasing revenue footprint in EMEA Shared values a
Slide 139: Financials
GRIFOLS 2022 Investor & Analyst Day FINANCIALS Investments in Plasma and Innovation Pipeline to Accelerate Growth and Profitability Alfredo Arroyo, CFO
Slide 140: Committed to Long-Term Growth
140 Committed to Long-Term Growth Strong Underlying Fundamentals 4.318 4.487 5.099 5.340 4.933 2017 2018 2019 2020 2021 • Global player in the attractive plasma market (7.2%1 CAGR2017-2020 for the industry) with strong position in the U.S. • Leaders in diagnostic solutions to screen whole-blood and
Slide 141: Doubling-Down Efforts to Increase Performance
141 Doubling-Down Efforts to Increase Performance in the Past 2 Years Reinforced plasma capabilities and capacities, supporting acceleration of plasma collections Biotest investment bolstering innovation, adding two unused plasma proteins Global footprint while strengthening presence in Europe, Chin
Slide 142: 2021 Key Financials
142 The decline in plasma volumes caused by COVID-19 was the primary driver of extraordinary financial impacts • Lower collections and higher cost per liter impacted revenues and margins particularly in H2 2021 • Strong underlying demand backed by price increases • Higher R&D and SG&A due to the int
Slide 143: Bioscience Constrained by Plasma Supply
143 Bioscience Constrained by Plasma Supply While the Other Divisions Grew in 2021 Bioscience Diagnostic Bio Supplies Hospital • Underlying demand strong of key proteins • Plasma supply constrained IG volume growth, especially in the U.S. • Strong performance of new product launches: Xembify® gainin
Slide 144: EBITDA and COVID Impact
144 1.219 1.223 1.434 1.324 961 106 220 503 28,2% 27,3% 28,1% 28,1% 27,6% -7,0% 0 1.000 2.000 2017 2018 2019 2020 2021 COVID Impact Transaction, restructuring, one-offs and Fx EBITDA Reported Reported / Underlying EBITDA Margin Underlying EBITDA Margin Revealed Strong Fundamentals 68 Sales volume 15
Slide 145: Investments in plasma and innovation pipeline
145 Investments in plasma and innovation pipeline… … to accelerate growth and profitability 145
Slide 146: Strategic Investments to Support Growth
146 ~1,000M in the past 2 years Strategically Invested to Support and Accelerate Growth Enhancing industrial capacities 332 308 281 2019 2020 2021 EUR 900+ million CAPEX in 3 years • New 6ML plasma fractionation plant in Clayton, North Carolina • World’s largest sterile purification and filling plan
Slide 147: Biotest: A Transformational Investment
147 Complementary Business to Boost Performance Biotest: A Transformational Investment 378 400 419 484 516 2017 2018 2019 2020 2021 Revenues (EUR in millions) CAGR: +8.1% Adjusted EBITDA2 75 92 100 108 101 19,8% 23,0% 23,9% 22,3% 19,5% -15% -10% -5% 0% 5% 10% 15% 20% 25% 30% 0 2017 2018 2019 2020 20
Slide 148: Investments in plasma and innovation pipeline
148 Investments in plasma and innovation pipeline… … to accelerate growth and profitability 148
Slide 149: Outlook H1 2022
149 Outlook H1 2022 Improving Performance in the First Half of 2022 • Accelerated plasma collections - already reached pre-COVID weekly levels • Price increases on key proteins • Robust underlying demand • Product mix driven by subcutaneous immunoglobulin (SCIG) • Higher alpha-1 patient base and str
Slide 150: Positive Performance for 2022 and Beyond
150 Positive Performance for 2022 and Beyond Plasma Collections expected to continue accelerating throughout 2022 driven by: Revenues Sound revenue growth stemming from Biopharma, supported by: • Strong underlying demand • Global price improvements • Product and geo mix • New and recently-acquired c
Slide 151: Commitment to Deleveraging Remains Firm
151 Despite Short-Term Challenges, Commitment to Deleveraging Remains Firm Deleveraging path supported by… Reinforcing our financial discipline 2 Business optimization Structural cost plan and R&D prioritization EUR 100M savings Cash dividends No cash dividends until leverage ratio <4x CAPEX Lowerin
Slide 152: Prepared to Respond to Macro-economic Context
152 Prepared to Respond to the Current Macro-economic Context Interest rates Optimized financial structure. Low exposure to interest rate hikes, since c.65% of debt tied to a fixed interest rate Inflation Inflationary pressures driving higher incentive to donate Impact on labor costs No significant
Slide 153: Low Exposure to Interest Rates Hike: 65% Fixed
153 Low Exposure to Interest Rates Hike: 65% Fixed Note: RCF not included and Euribor considered as fixed interest 35% 65% Floating Fixed Total debt Interest structure EUR floating debt 13% of total debt outstanding USD floating debt 22% of total debt outstanding 153
Slide 154: Key Takeaways: Financials
154 Investments in Plasma and Innovation Pipeline to Accelerate Growth and Profitability During 2020 and 2021, Grifols invested to drive further revenue growth and margin expansion Plasma collection momentum supports sequential performance improvement Delivered on commitments: divestments and cost o
Slide 155: Final Remarks
GRIFOLS 2022 Investor & Analyst Day FINAL REMARKS Delivering on Commitments Outlined in 2020 and 2021 Victor Grifols Deu, co-CEO
Slide 156: Our Commitments
156 Our Commitments Accelerating innovation and optimizing our portfolio Gaining focus on Biopharma, Plasma Procurement, Diagnostics and Bio Supplies Optimizing our business: Divestments and cost optimization Streamlined our organizational model Core Business Innovation Organization + Leveraging sus
Slide 157: Accelerating Innovation and Optimizing Our Portfolio
157 Accelerated and focus on priority projects Accelerating Innovation and Optimizing Our Portfolio… Re-prioritized R&D projects R&D collaboration agreement + 8 projects discontinued ~€30M savings Reinforced by Biotest R&D pipeline + Expanding our innovation footprint… RTP, NC Biopharma Düdingen, Sw
Slide 158: Strong Pipeline Enhanced by Grifols' Scalability
158 … With Strong Pipeline Enhanced by Grifols’ Scalability and Broader Commercial Reach …strengthened with Biotest acquisition + Accelerated priority projects… Market potential Fibrinogen® Trimodulin USD 400-800M USD 1Bn+ CMV IG Hyper USD 200-300M Market potential Xembify® in SID (CLL) ATIII in Sep
Slide 159: Strong Business Fundamentals Support Biotest Acquisition
159 Biopharma | Strong Business Fundamentals Support Biotest Acquisition 1 North America Europe MEA 313 donor centers 3 manufacturing sites 89 donor centers 3 manufacturing sites 1 donor center (+19 planned for 2022 & 2023) 1 manufacturing site Note: number of plasma centers as of June 30, 2022 +31
Slide 160: Securing U.S. NAT Business While Untapping China
160 Distribution agreement through SRAAS + CTS agreement Long-term agreement: • CTS will operate Grifols testing labs • Grifols will supply NAT instrumentation and testing Diagnostic | Securing U.S. NAT Business While Untapping China Opportunity Through SRAAS Agreement •Integrated commercial model c
Slide 161: Bio Supplies: High Growth and Profitability Business
161 Bio Supplies | High Growth and Profitability Business With the Full Integration of Access Biologicals Key customers: Biotechnology research & manufacturing and Diagnostic industries Vertical integration to obtain higher margin from Grifols products Commercial knowledge to grow in cell culture ma
Slide 162: Optimizing Our Business
162 Optimizing Our Business | Focusing On Value-Creation Businesses While Achieving Structural Cost Savings Divestments Cost optimization Structural Cost reduction R&D prioritization +€100M annualized savings Optimizing business + Hemostasis Oct’21 Blood Bags Nov’21 Hospital Software BU Already agre
Slide 163: Evolving Our Organization to Reinforce Competitiveness
163 Evolving Our Organization to Reinforce Competitiveness Biopharma Plasma Procurement Diagnostic Bio Supplies Others (Healthcare Solutions) Operations Co-CEOs New organization Full-fledged Business Units 1 Streamlined value-driven organization 2 End-to-end business ownership 3 Streamlined Value-Dr
Slide 164: Key Takeaways: Delivering on Commitments
164 Key Takeaways Delivering on Commitments Outlined in 2020 and 2021 CAGR: +8.1% (at cc) Stable Cost per Liter while increasing plasma supply EBITDA: 28% 2017 Continuous growth and value creation Supported by strong underlying demand, pricing environment and product/geographical mix coupled with pl
Slide 165: June 30, 2022
Sika © June 30, 2022
Slide 166: Glossary
Glossary
Slide 167: Glossary
167 Glossary • Alpha-1 antitrypsin deficiency (AATD): Inherited disease characterized by low levels of, or no,alpha-1 antitrypsin (AAT) in the blood. This protein made in the liver, reaches other organs (such as the lungs), after being released into the blood stream, enabling its normal function • A
Slide 168: Glossary
168 Glossary • Factor VIII or FVIII: This is an essential blood clotting factor also known as anti-hemophilic factor (AHF). In humans, Factor VIII is encoded by the F8 gene.Defects in this gene results in hemophilia A, a gender linked disease that occurs predominantly in males. FVIII concentrated fr
Slide 169: Glossary
169 Glossary • Hemotherapy: Treatment of a disease using blood, blood components and its derivatives • HIV: Human Immunodeficiency Virus • Hyperimmune globulins: type of immunoglobulins prepared in a manner similar to human normal immunoglobulin, except that the donor has high titers of antibodies a
Slide 170: Glossary
170 Glossary • Molecular Diagnostic: Discipline that studies genomic (DNA) and proteomic (proteins)expression patterns and uses the information to distinguish between normal, precancerous, and canceroustissues at the molecular level • Monoclonal antibody (mAb): Antibody produced by a single clone of
Slide 171: Glossary
171 Glossary • Plasmapheresis: Plasmapheresis is a technique which separates plasma from other blood components, such as red blood cells, platelets and other cells. These unused blood components are suspended in saline solution and immediately reinjected back into the donor. Because the donor is onl
Slide 172: Glossary
172 Glossary • Rh (Rhesus) blood group system: Most important blood group system after ABO. The Rh blood group system consists of 50 defined blood-group recombinant proteins, among which the five recombinant proteins D,C, c, E and are the most important. The commonly used terms Rh factor, Rh positiv